Feb. 3 at 10:34 PM
$NAGE In response to a comment on Reddit regarding the need for another catalyst to get the stock price back on track, I posted this in agreement about NoPark, but added: I have a similar opinion, but if one hopes for a big price move up, it will depend on positive NoPark results. NoPark is the first shot on goal, and the next ones are more than a year away. There might be an exception to that regarding the Norwegian Long COVID (LC) trial. As I understand, LC is regarded as a disease by the EU's drug agency, unlike the FDA. That might be a plus and a minus. Niagen Bio could promote the results in the US, and it could develop Niagen as a drug in Europe. The trial is at Phase 2 with 310 participants, but not identified as one associated with the FDA (which is consistent with LC not being classified as a disease in the US). It is very likely the trial that Rob Fried briefly referred to when a question arose regarding the Boston LC trial results. (continued)
